Seminars in Perinatology
Volume 31, Issue 6 , Pages 363-371 , December 2007

Immunosuppressant Therapy in Pregnant Organ Transplant Recipients

  • Karin M. Fuchs, MD

      Affiliations

    • Division of Maternal Fetal Medicine, Columbia University Medical Center, New York, NY.
    • Corresponding Author InformationAddress reprint requests to Karin M. Fuchs, MD, Division of Maternal Fetal Medicine, Columbia Presbyterian Medical Center, 622 West 168th Street, PH 16, New York, NY 10032.
    • ,
  • Donald R. Coustan, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital of Rhode Island, Providence, RI.

References 

  1. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2004;103–114
  2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715–2729
  3. Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209
  4. http://www.fda.gov
  5. Sibanda N, Briggs JD, Davison JM, et al. Pregnancy after organ transplantation: a report from the UK Transplant pregnancy registry. Transplantation. 2007;83:1301–1307
  6. Sgro MD, Barozzino T, Mirghani HM, et al. Pregnancy outcome post renal transplantation. Teratology. 2002;65:5–9
  7. Sibley CP, Boyd RDH. Mechanisms of transfer across the human placenta. In:  Fox PA editors. Fetal and Neonatal Physiology. Philadelphia, PA: WB Saunders Company; 2004;p. 111
  8. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43:487–514
  9. Marin JJ, Briz O, Serrano MA. A review on the molecular mechanisms involved in the placental barrier for drugs. Curr Drug Deliv. 2004;1:275–289
  10. Green TP, O’Dea RF, Mirkin BL. Determinants of drug disposition and effect in the fetus. Annu Rev Pharmacol Toxicol. 1979;19:285–322
  11. Venkataramanan R, Koneru B, Wang CC, et al. Cyclosporin and its metabolites in mother and baby. Transplantation. 1988;46:468–469
  12. Nandakumaran M, Eldeen AS. Transfer of cyclosporin in the perfused human placenta. Dev Pharmacol Ther. 1990;15:101–105
  13. Flechner SM, Katz AR, Rogers AJ, et al. The presence of cyclosporine in body tissues and fluids during pregnancy. Am J Kidney Dis. 1985;5:60–63
  14. Bourget P, Fernandez H, Delouis C. Accumulation of cyclosporine in the conceptus during the first trimester of pregnancy after liver transplantation. Transplantation. 1991;51:1306–1307
  15. Jain A, Venkataramanan R, Fung JJ, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation. 1997;64:559–565
  16. de Boer NK, Jarbandhan SV, de Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol. 2006;101:1390–1392
  17. Ballard PL, Granberg P, Ballard RA. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. J Clin Invest. 1975;56:1548–1554
  18. Beitins IZ, Bayard F, Ances IG, et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr. 1972;81:936
  19. Blanford AT, Murphy BE. In vitro metabolism of prednisone, dexamethasone, and cortisol by the human placenta. Am J Obstet Gynecol. 1977;127:264–267
  20. Anderson GG, Rotchell Y, Kaiser DG. Placental transfer of methylprednisolone following maternal intravenous administration. Am J Obstet Gynecol. 1981;140:699–701
  21. Pinsky L, DiGeorge AM. Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. Science. 1965;147:402
  22. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet. 1999;86:242
  23. Schatz M, Patterson R, Zeitz S, et al. Corticosteroid therapy for the pregnant asthmatic patient. JAMA. 1975;233:804
  24. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62:385
  25. Githens JH, Rosenkrantz JG, Tunnock SM. Teratogenic effects of azathioprine (Imuran). J Pediatr. 1965;66:959–961
  26. Rosenkrantz JG, Githens JH, Cox SM, et al. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol. 1967;97:387–394
  27. Williamson RA, Karp LE. Azathioprine teratogenicity: review of the literature and case report. Obstet Gynecol. 1981;58:247–250
  28. Tallent MB, Simmons RL, Najarian JS. Birth defects in child of male recipient of kidney transplant. JAMA. 1970;211:1854–1855
  29. McKay DB, Josephson MA, Armenti VT, et al. Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant. 2005;5:1592–1599
  30. EBPG Expert Group in Renal Transplantation. European best practice guidelines for renal transplantation (Section IV. 10. Long-term management of the transplant recipient – pregnancy in renal transplant recipients). Nephrol Dial Transplant. 2002;17(suppl 4):50–55
  31. Sifontis NM, Coscia LA, Constantinescu S, et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82:1698–1702
  32. Le Ray C, Coulomb A, Elefant E, et al. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol. 2004;103:1091–1094
  33. Tjeertes IF, Bastiaans DE, van Ganzewinkel CJ, et al. Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use. J Perinatol. 2007;27:62–64
  34. Package Insert: CELLCEPT® (mycophenolate mofetil capsules); Roch Laboratories. Revised October 2005
  35. Mason RJ, Thomson AW, Whiting PH, et al. Cyclosporin-induced fetotoxicity in the rat. Transplantation. 1985;39:9
  36. Tendron-Franzin A. Long-term effects of in utero exposure to cyclosporin A on renal function in the rabbit. J Am Soc Nephrol. 2004;15:2687–2693
  37. Farley DE, Shelby J, Alexander D, et al. The effect of two new immunosuppressive agents. FK506 and didemnin B, in murine pregnancy Transplantation. 1991;52:106–110
  38. Jankowska I, Oldakowska-Jedynak U, Jabiry-Zieniewicz Z, et al. Absence of teratogenicity of sirolimus used during early pregnancy in a liver transplant recipient. Transplant Proc. 2004;36:3232–3233
  39. Guardia O, Rial Mdel C, Casadei D. Pregnancy under sirolimus-based immunosuppression. Transplantation. 2006;81:636
  40. Armenti VT, Moritz MJ, Cardonick EH, et al. Immunosuppression in pregnancy: choices for infant and maternal health. Drugs. 2002;62:2361–2375
  41. Prakash , Gupta V, Singh SM, et al. Effect of intrauterine exposure of murine fetus to cyclophosphamide on development of thymus. Immunopharmacol Immunotoxicol. 2007;29:17–30
  42. Kirshon B, Wasserstrum N, Willis R, et al. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol. 1988;72:462
  43. Enns GM, Roeder E, Chan RT, et al. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?. Am J Med Genet. 1999;86:237
  44. Paladini D, Vassallo M, D’Armiento MR, et al. Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy. Birth Defects Res A Clin Mol Teratol. 2004;70:99
  45. Zemlickis D, Lishner M, Erlich R, et al. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen. 1993;13:139
  46. Brent RL. Teratogen update: reproductive risks of leflunomide (Arava) (A pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide ho are contemplating fathering a child). Teratology. 2001;63:106–112
  47. Takahashi N, Nishida H, Hoshi J. Severe B cell depletion in newborns from renal transplant mothers taking immunosuppressive agents. Transplantation. 1994;57:1617–1621
  48. Di Paolo S, Schena A, Morrone LF, et al. Immunologic evaluation during the first year of life of infants born to cyclosporin-treated female kidney transplant recipients: analysis of lymphocyte subpopulations and immunoglobulin serum levels. Transplantation. 2000;69:2049–2054
  49. Heeg K, Bendigs S, Wagner H. Cyclosporin A prevents the generation of single positive (Lyt2+L3T4-. Lyt2-L3T4+) mature T cells but not single positive (Lyt2+T3-) immature thymocytes in newborn mice Scand J Immunol. 1989;30:703–710
  50. Schen FP, Stallone G, Schena A, et al. Pregnancy in renal transplantation: immunologic evaluation of neonates from mothers with transplanted kidney. Transpl Immunol. 2002;9:161–164
  51. Davison JM, Dellagrammatikas H, Parkin JM. Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol. 1985;92:233–239
  52. Cimaz R, Meregalli E, Biggioggero M, et al. Response to tetanus vaccination in infants exposed in utero to immunosuppressants for maternal autoimmune disorders. Lupus. 2007;16:129–132
  53. Willis FR, Findlay CA, Gorrie MJ, et al. Children of renal transplant recipient mothers. J Paediatr Child Health. 2000;36:230–235
  54. Stanley CW, Gottlieb R, Zager R, et al. Developmental well-being in offspring of women receiving cyclosporin post-renal transplant. Transplant Proc. 1999;31:241–242
  55. Stratta P, Canavese C, Giacchino F, et al. Pregnancy in kidney transplantation: satisfactory outcomes and harsh realities. J Nephrol. 2003;16:792–806
  56. Gaughan WJ, Moritz MJ, Radomski JS, et al. National Transplantation Pregnancy Registry: report on outcomes in cyclosporine-treated female kidney transplant recipients with an interval from transplant to pregnancy of greater than five years. Am J Kidney Dis. 1996;28:266–269
  57. Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies; a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992;166:1318–1323
  58. Reinisch JM, Simon NG. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science. 1978;202:436–438
  59. Scott JR. Fetal growth retardation associated with maternal administration of immunosuppressives. Am J Obstet Gynecol. 1977;128:668–676
  60. Guller S, Kong L, Wozniak R, et al. Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: a potential role in preterm rupture of the fetal membranes. J Clin Endocrinol Metab. 1995;80:2244
  61. Lockwood CJ, Radunovic N, Nastic D, et al. Corticotropin-releasing hormone and related pituitary adrenal axis hormones in fetal and maternal blood during the second half of pregnancy. J Perinat Med. 1996;24:243–251
  62. Speake PF, Zipitis CS, Houston A, et al. Taurine transport into fetal cord blood cells: inhibition by cyclosporine A. J Soc Gynecol Invest. 2004;11:472–477
  63. Day C, Hewins P, Sheikh L, et al. Cholestasis in pregnancy associated with ciclosporin therapy in renal transplant recipients. Transpl Int. 2006;19:1026–1029
  64. Kainz A, Harabacz I, Cowlrick IS, et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000;70:1718
  65. Jain AB, Shapiro R, Scantlebury VP, et al. Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center’s experience. Transplantation. 2004;77:897–902
  66. Muirhead N, Sabharwal AR, Rieder MJ, et al. The outcome of pregnancy following renal transplantation: the experience of a single center. Transplantation. 1992;54:429–432
  67. Katz FH, Duncan BR. Entry of prednisone into human milk. N Engl J Med. 1975;293:1154
  68. Greenberger PA, et al. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther. 1993;53:324–328
  69. Coulam CB, Moyer TP, Jiang NS, et al. Breast-feeding after renal transplantation. Transplant Proc. 1982;14:605–609
  70. Ito S, Blajchman A, Stephenson M, et al. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;1993:1393–1399
  71. Grekas DM, Vasiliou SS, Lazarides AN. Immunosuppressive therapy and breast-feeding after renal transplantation. Nephron. 1984;37:68
  72. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–789
  73. Moretti ME, Verjee Z, Ito S, et al. Breast-feeding during maternal use of azathioprine. Ann Pharmacother. 2006;40:2269–2272
  74. Sau A, Clarke S, Bass J, et al. Azathioprine and breastfeeding: is it safe?. Br J Obstet Gynaecol. 2007;114:498–501
  75. Nyberg G. Breast-feeding during treatment with cyclosporin. Transplantation. 1998;65:253–255
  76. Munoz-Flores-Thiagarajan KD, Easterling T, Davis C, et al. Breast-feeding by a cyclosporin-treated mother. Obstet Gynecol. 2001;97:816–818
  77. Moretti ME, Sgro M, Johnson DW, et al. Cyclosporin excretion into breast milk. Transplantation. 2003;75:2144–2146
  78. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2003;131–141
  79. Gardiner SJ, Begg EJ. Breastfeeding during tacrolimus therapy. Obstet Gynecol. 2006;107:453–455
  80. French AE, Soldin SJ, Soldin OP, et al. Milk transfer and neonatal safety of tacrolimus. Ann Pharmacother. 2003;37:815–818

PII: S0146-0005(07)00110-3

doi: 10.1053/j.semperi.2007.09.006

Seminars in Perinatology
Volume 31, Issue 6 , Pages 363-371 , December 2007

Article Tools